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Background: MicroRNAs (miRNAs) bind to mRNAs and target them for translational inhibition or transcriptional
degradation. It is thought that most miRNA-mRNA interactions involve the seed region at the 5′ end of the miRNA.
The importance of seed sites is supported by experimental evidence, although there is growing interest in interactions
mediated by the central region of the miRNA, termed centered sites. To investigate the prevalence of these interactions,
we apply a biotin pull-down method to determine the direct targets of ten human miRNAs, including four isomiRs that
share centered sites, but not seeds, with their canonical partner miRNAs.
Results: We confirm that miRNAs and their isomiRs can interact with hundreds of mRNAs, and that imperfect centered
sites are common mediators of miRNA-mRNA interactions. We experimentally demonstrate that these sites can repress
mRNA activity, typically through translational repression, and are enriched in regions of the transcriptome bound by
AGO. Finally, we show that the identification of imperfect centered sites is unlikely to be an artifact of our protocol
caused by the biotinylation of the miRNA. However, the fact that there was a slight bias against seed sites in our
protocol may have inflated the apparent prevalence of centered site-mediated interactions.
Conclusions: Our results suggest that centered site-mediated interactions are much more frequent than previously
thought. This may explain the evolutionary conservation of the central region of miRNAs, and has significant implications
for decoding miRNA-regulated genetic networks, and for predicting the functional effect of variants that do not alter
protein sequence.Background
MicroRNAs (miRNAs) are small non-coding RNAs (ap-
proximately 22 nucleotides) that regulate the expression
of protein-coding genes in association with the RNA-
induced silencing complex (RISC). They are present in
most eukaryotic cells, have been predicted to affect the
expression of over 60% of mammalian genes [1], and
have been implicated in multiple cellular processes and
human diseases. They can repress their targets via sev-
eral mechanisms: preventing translation initiation or
elongation, directing mRNA cleavage, and prompting* Correspondence: nicole.cloonan@qimrberghofer.edu.au
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reproduction in any medium, provided the ormRNA decay [2]. It was thought that miRNA-mRNA in-
teractions almost always involved contiguous and perfect
Watson-Crick base-pairing between the miRNA 'seed re-
gion' and the mRNA target [3], and that binding outside
the seed served to augment imperfect seed binding [3].
The attractive simplicity of using nucleotide comple-
mentarity to identify mRNA targets has given rise to
many bioinformatics tools. These are based (to differing
extents) on complementarity to the seed, evolutionary
conservation, and free energy of binding [4]. The pres-
ence of canonical seed sites (in the absence of other
more extensive complementarity to the miRNA) is by
far the most discriminatory feature for target prediction
[5], and incorporation of other modes of binding dra-
matically reduces the accuracy of these programs [6,7].
However, results from our lab [8] and others [6,9,10]
suggest that even the best algorithms have false positiveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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absent from these predictions. In order to comprehen-
sively understand the cohort of direct miRNA targets,
unbiased transcriptome-wide experimental methods are
needed.
A common experimental approach to determining
miRNA targets has been to transfect cells with an ex-
ogenous miRNA or knock down an endogenous one and
measure the resulting change in mRNA or protein levels
of each gene [6,7]. This approach is problematic because
many of the effects observed may be due to changes in
the levels of transcription factors that are targeted by the
miRNA, rather than being direct consequences of miRNA
binding [8]. Sequencing-based methods such as high-
throughput sequencing of RNAs isolated by crosslinking
immunoprecipitation (HITS-CLIP) and photoactivatable-
ribonucleoside-enhanced crosslinking and immunoprecip-
itation (PAR-CLIP) [11,12] identify fragments of mRNA
bound by Argonaute proteins (usually AGO2) and a pool
of miRNAs, and infer the interactions between them
bioinformatically (Figure 1A). This approach is an excel-
lent tool to understand the genome-wide occupancy of
RISCs, but is not suitable for the comparative evaluation
of sites between closely related miRNAs, since it does not
retain the information about which miRNAs are bound to
which sites. An alternative approach is to transfect cells
with a synthetic biotinylated miRNA, perform streptavidin
purification, and profile the captured mRNA population
via microarray or sequencing (Figure 1B) [13-18]. Al-
though the introduction of a synthetic molecule into a
cellular system is not ideal, this approach provides high-
quality data for the inference of binding sites for single
miRNAs, and provides the opportunity to measure target
affinity between very closely related miRNAs, even those
with a single nucleotide difference [13].
While most experimental effort has been directed at
verifying seed-based interactions, non-seed based inter-
actions have also been demonstrated, albeit far less fre-
quently [3,7,19,20]. The most common variations appear
to be 'seed-like' with mismatches or wobble in positions
5, 6, and 7 [20], and 'G-bulge' sites, in which the mRNA
nucleotide that would normally pair with position 6 of
the miRNA is bulged out of the interaction [19]. The
strong evolutionary conservation of the central region of
miRNAs [7] prompted a successful search for 'centered
site'-mediated miRNA activity, demonstrating that 11
nucleotides of perfect complementarity starting at pos-
ition 3, 4 or 5 could inhibit mRNA translation [21].
However, these centered sites were found only occasion-
ally within the human transcriptome, similar in fre-
quency to the 3′ supplementary and 3′ complementary
sites that together account for <10% of interactions [3].
It remains an open question as to why the central region
of miRNAs is strongly conserved; it may be driven bymiRNA-mRNA interactions and/or by miRNA biogen-
esis. We hypothesized that imperfect centered sites
could mediate miRNA-mRNA interactions, and that
they are more commonly used than results from degra-
dome sequencing would suggest. To test this hypothesis,
we employed the biotin pull-down approach [13] to
identify the direct miRNA targets for 10 carefully se-
lected miRNAs (Table S1 in Additional file 1). We
included two closely related miRNAs, miR-10a and miR-
10b, which share identical seed sites, but differ by a sin-
gle nucleotide in the center region. We also included
four shifted isomiRs, which are miRNAs produced from
the same pre-miRNA as the 'canonical' mature miRNA,
but differing in 5′ and/or 3′ end cleavage [13,22]. These
isomiRs provide an ideal naturally occurring biological
control, as the centered sites are shared between a
miRNA and its isomiR, whilst the seed sites differ
(Figure 1C). We show that imperfect-centered sites are
common mediators of mRNA interactions, a finding that
may explain the evolutionary conservation of the central
region of miRNAs, and that will be important for decod-
ing miRNA-regulated genetic networks.
Results
Biotin pull-downs identify hundreds of miRNA-mRNA
interactions
To identify direct miRNA targets, we transfected 4 × 106
HEK293T cells with 200 pmols synthetic biotinylated
miRNA duplexes (Table S1 in Additional file 1). This
very low ratio of duplex to cells was critical to avoid
some of the problems with introducing an exogenous
molecule on miRNA-mRNA stoichiometry, and we
confirmed that transfection at this level made no sub-
stantial alterations to endogenous transcriptional net-
works (Figure S1A in Additional file 2). We then
performed streptavidin purifications, and profiled the
captured mRNA population via microarrays. At a 5%
false discovery rate (FDR; see Materials and methods),
between 963 (miR-10b-iso) and 2,261 (miR-182) micro-
array probes detected significantly higher expression in
the biotin pull-down samples than in the mock-
transfected controls (Table 1). The distribution of fold-
changes observed for each miRNA duplex is plotted in
Additional file 3. We considered the Ensembl (V62)
transcripts with exact matches to these probes to be pu-
tative targets of the miRNA, identifying an average of
1,572 target genes per miRNA (Table 1). These numbers
correspond well to those obtained by other experimental
approaches [12,23,24].
Predicted and validated targets are significantly enriched
in the biotin pull-downs
Luciferase assays are usually considered to be the ‘gold
standard’ for validating miRNA-mRNA interactions. We
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Figure 1 Methods for ascertaining miRNA targets. (A) In the HITS-CLIP method [11], RISC is pulled down using an antibody against
AGO2. RNAse digestion then reduces the full length mRNA targets to short fragments that can be sequenced along with the miRNAs using
high-throughput sequencing. This method uncovers RISC occupancy on individual transcripts and therefore captures the binding sites, but it
cannot directly link them to a particular miRNA. This information must be inferred from the pool of miRNAs present. (B) In this study we
employed a biotin pull-down method [13], in which a synthetic biotinylated miRNA is transfected into cells, integrates into RISC, and is then
pulled down using streptavidin beads. The associated mRNAs are then profiled by microarray or RNAseq. This method does not reveal the exact
miRNA binding sites, but it does preserve the relationship between the miRNA and its targets, allowing the exploration of closely related miRNA
species. (C) We examined four shifted isomiRs and their canonical partners, which have different seed sites but share centered sites (defined as
11 bp starting at position 3, 4 or 5). miR-17-5p and its isomiR are illustrated here.
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Table 1 Number of inferred targets for each miRNA
tested
miRNA Probes Transcripts Genes
miR-10a 2,206 5,963 1,887
miR-10a-iso 1,648 4,211 1,468
miR-10b 1,588 3,940 1,365
miR-10b-iso 963 2,235 889
miR-17-5p 1,223 2,862 1,137
miR-17-5p-iso 1,656 3,731 1,461
miR-182 2,261 6,423 2,008
miR-182-iso 1,569 4,316 1,444
miR-23b 2,248 5,383 1,990
miR-27a 2,334 5,310 2,069
Probes: number of probes significantly enriched in pull-downs compared to
controls (5% FDR). Transcripts: number of transcripts to which those probes
map exactly. Genes: number of genes from which those transcripts originate.
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down results and miRNA targets that have been con-
firmed by luciferase assays in the literature (Table S2 in
Additional file 1). We excluded genes that were not tar-
geted by an Illumina microarray probe (and therefore
could not be detected by our biotin pull-down) or that
were not expressed in HEK293T cells, leaving 93 genes for
this analysis. Forty-three previously validated targets were
enriched by biotin pull-downs (Table S2 in Additional
file 1) in HEK293T cells, which was significantly more
than expected by chance (Table S3 in Additional file 1;
Fisher’s exact test (FET), P-value <1.01 × 10-12). Interest-
ingly, a lower proportion of targets validated in non-HEK
cell lines were confirmed by our biotin pull-down (43.2%)
than targets validated in HEK cell lines (51.4%), suggesting
that cell type-specific factors can lower the concordance
between orthogonal validation methods.
As a second control, we examined the number of
bioinformatically predicted targets in our biotin pull-
downs. Although bioinformatic predictions have many
false positives (and an as yet undefined level of false
negatives) [6,8-10], we would still expect to see an
enrichment for predicted targets in each of our biotin
pull-downs. Importantly, predictions can be made for
the isomiRs used in this study, for which very few lucif-
erase assays (or other experimental validation of targets)
have been performed. We used TargetScan [1] to predict
targets for each miRNA and isomiR, and compared each
list to the significantly enriched genes in the correspond-
ing pull-down. In each case, we observed an enrichment
of TargetScan-predicted genes in the pull-down fraction
(Figure 2A; Figure S1B,C in Additional file 2), and the
overlap was significantly more than expected by chance
(Table S3 in Additional file 1; FET, P < 9 × 10-180). We
selected eight previously untested targets of miR-17-5p
(3) and miR-27a (5) for experimental validation usingluciferase assays. TargetScan-predicted binding sites were
cloned into the 3′ UTR of a luciferase reporter construct,
and co-transfected into HEK293T cells with either their
predicted miRNA mimic or a control mimic. We found
that seven of eight target sites had significantly (P ≤ 0.05)
reduced luciferase activity in the presence of a miRNA
mimic compared to the control mimic (Figure 2B). As the
rate of validation seen here (87.5%) greatly exceeds the
validation rate of TargetScan predictions alone (39%) [8],
this provides substantial experimental evidence that the
biotin pull-downs are enriching for genuine and direct tar-
gets of the miRNAs.
As a third control, we compared the biotin pull-down
results to those obtained using both PAR-CLIP [12] and
miR-17-5p over-expression studies [23,24]. The PAR-
CLIP experiment was conducted in HEK293 cells, which
differs from the HEK293T cells used in our experiments
by the exogenous expression of the SV40 large T antigen.
This protein binds to and inactivates the p53 transcrip-
tion factor [25], so the gene expression patterns between
these cell lines differ. The over-expression experiments
were also performed in very different cell lines (human
umbilical vein endothelial cells (HUVECs) [23] and
HCT116 cells [24]), and therefore we do not expect a
perfect overlap between the targets detected between
these orthogonal methods. By comparing the distribu-
tion of the miR-17-5p fold-change observed in this study
between the transcripts that were detected as targets in
previous studies and those that were not, we observed
a significantly greater fold-change in the corresponding
biotin pull-down in the former class (Figure 2C-E;
Additional file 4; Kolmogorov-Smirnov tests, P-values
from 1 × 10-2 to 1 × 10-22). Additionally, the overlaps be-
tween our inferred miRNA target sets and those de-
duced from the other studies were significantly greater
than expected by chance (Table S3 in Additional file 1;
FET, P-values from 4.68 × 10-2 to 5.17 × 10-20), although
the enrichment was modest (odds ratio (OR) = 1.85; 95%
confidence interval (CI) 1.7 to 2.1). Finally, although
biotin-labeled miRNAs have been previously shown to
incorporate into RISC [17], we wanted to be sure that
our results were dependent on RISC association, and
not due to cytoplasmic binding of free biotin-labeled
miRNAs. To test this, we performed a hybrid AGO
immune-precipitation and biotin pull-down (Figure 2F).
HEK293T cells were transfected with either a stand-
ard biotinylated, double-stranded miR-17-5p miRNA
duplex, or with a biotinylated single-stranded miR-17-5p
sequence. Cells were lysed and subject to AGO immune-
precipitation, creating an AGO2 enriched and AGO2-
depleted fraction. Each fraction was then subject to a
biotin pull-down, and the relative enrichment compared
to input RNA (Figure 2F) was measured by quantitative
RT-PCR (qRT-PCR). We specifically assessed the levels of
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(See figure on previous page.)
Figure 2 Biotin pull-downs identify bone fide miRNA targets. (A) Volcano plot showing the significance of the difference in expression
between the miR-17-5p pull-down and the mock-transfected control, for all transcripts expressed in HEK293T cells. Both targets predicted by
TargetScan or validated previously via luciferase assay were significantly enriched in the pull-down compared to the controls. (B) Results from
luciferase assays on previously untested targets predicted using TargetScan and uncovered using the biotin pull-down. The plot indicates mean
luciferase activity from either the empty plasmid or from pMIR containing a miRNA binding site in the 3′ UTR, relative to a negative control.
Asterisks indicate a significant reduction in luciferase activity (one-sided t-test; P < 0.05) and error bars the standard error of the mean over three
replicates. (C-E) Targets identified through PAR-CLIP or through miRNA over-expression studies show greater enrichment in the pull-down.
Cumulative distribution of log fold-change in the pull-down for transcripts identified as targets by the indicated miRNA over-expression study
or not. Red, canonical transcripts found to be miR-17-5p targets in the indicated study (Table S5 in Additional file 1); black, all other canonical
transcripts; p, one-sided P-value from Kolmogorov-Smirnov test for a difference in distributions. (F) To confirm that our results were dependent on
RISC association, cells were transfected with either single or double-stranded synthetic miRNAs, then subjected to AGO2 immunoprecipitation. The
biotin pull-down was performed in the AGO2-enriched and AGO2-depleted fractions. (G-H) Quantitative RT-PCR revealed that, with double-stranded
(ds) miRNA (G), four out of five known targets were enriched relative to input mRNA (*P≤ 0.05, **P < 0.01, ***P < 0.001) in the AGO2-enriched but not
in the AGO2-depleted fractions, but this enrichment was not seen for the cells transfected with a single-stranded (ss) miRNA (H). The numbers on the
x-axis correspond to those in Figure 2F. Error bars represent the standard error of mean (sem).
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two previously validated miRNA binding sites [8]. As
endogenous RISC loading preferentially requires double-
stranded miRNA duplexes [26,27], we would expect
double-stranded but not single-stranded molecules to en-
rich for targets in an AGO2 precipitation. Four of five tar-
gets were found to be enriched in the AGO2 enriched
fraction when a double-stranded molecule was used
(Figure 2G), and but not when a single-stranded molecule
was used (Figure 2H). This, when considered along with
the data presented above, confirms that the biotin pull-
down is consistently enriching for genuine targets of
miRNAs, although we do not know if or how these inter-
actions result in target repression.
Biotin pull-downs are less likely to enrich for destabilized
mRNAs, but have low rates of false positive target
identification
If we are to use the biotin pull-downs to characterize
non-seed site interactions, then it is important to under-
stand the limitations of this protocol. To start character-
izing the potential false negatives of the biotin pull-down
approach, we selected six genes that we had previously re-
ported to be targets of miR-17-5p that were not enriched
in our pull-down [8]. We used qRT-PCR to determine
whether these mRNA targets were destabilized by miR-
17-5p and therefore less likely to appear as significantly
enriched in the biotin pull-down. After transient transfec-
tion with biotinylated miR-17-5p (replicating the condi-
tions of the biotin pull-down) we observed significant
degradation of five of the six genes (Additional file 5). This
result suggests that mRNA degradation probably affects
whether or not a target can be detected via the biotin pull-
down approach, and suggests that the concordance be-
tween biotin pull-down and luciferase assay could be
higher when only comparing targets that are translation-
ally regulated.
We then wished to examine the impact of transcrip-
tional complexity on our interpretation of the microarrayresults. Specifically, we were curious about the subset of
transcripts (average 19%) that were significantly enriched
in the pull-down but that had no predicted binding sites
(either seed sites or any type of centered sites, discussed
below) in their annotated exons. We hypothesized that
this set may contain examples of unannotated exons and
that this could lead to the incorrect classification of these
targets as false positives. To investigate this possibility, we
performed strand-specific RNAseq from the RNAs cap-
tured in the biotinylated miR-17-5p pull-down experi-
ment. We examined all 26 HUGO genes that were
targeted by an Illumina probe that was significantly
enriched in the pull-down, that had exact matches only to
transcripts with no predicted miR-17-5p seed and perfect
or imperfect centered binding sites, and that predomin-
antly spanned unique genomic regions to which the se-
quencing reads could be mapped [28]. Of these, eight
clearly had either extended 3′ UTRs (HMBOX1, TBPL1,
ZNF786, NDUFAF3) or retained introns (C2orf34, COQ
10B) or both (C16orf68, EEF1E1), and, in all cases, these
extra regions contained miR-17-5p seed or centered sites
(Figure 3). Two additional genes (ERLEC1, UBB) showed
weak evidence for retained introns or extended 3′ UTRs
that contained miR-17-5p sites. This suggests that almost
40% of the genes that we had initially assumed to be false
positives were in fact likely to be true targets.
Hundreds of miRNA-mRNA interactions are mediated by
centered sites
Having confirmed to our satisfaction that the biotin
pull-downs could provide a high level of sensitivity for
examining non-seed mediated interactions, we then
searched for putative seed and perfect or imperfect cen-
tered binding sites (Figure 1C; Additional file 6) of each
of our 10 miRNAs in the transcripts detected by the
microarray probes. We asked what proportion of puta-
tive miRNA targets could be explained by the presence
of these sites (Additional file 7). Studies that measured
the change in protein output after miRNA transfection
AB
Figure 3 miRNA binding in unannotated exons. Sequencing the RNA captured in the miR-17-5p pull-down revealed several examples of
targeting outside annotated exons. The red wiggle plot along the top indicates the number of reads from the RNAseq library that mapped
at each position. Illumina microarray probes highlighted in blue showed significant enrichment in the biotin pull-down. (A,B) HMBOX1 (A)
encodes a homeobox-containing transcription factor and EEF1E1 (B) a translation elongation factor. Probes detecting these genes were
significantly enriched in the pull-down (adjusted P-values: ILMN_1843949, 0.002; ILMN_1725105, 0.03). None of the annotated exons (maroon
boxes) contained predicted miR-17-5p sites. However, the RNAseq data suggested that both genes had retained introns that resulted in a
longer 3′ UTR, and this region did contain binding sites.
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fold-change < -0.5) had a seed site [6,10] for the relevant
miRNA. Hafner et al. [12] reported that 50% of their
PAR-CLIP clusters contained a seed site for one of the
top 100 most expressed miRNAs in HEK293 cells. We
found that, on average, 41.3% (standard deviation 10.1%)
of significantly enriched transcripts contained one or
more seed sites for the biotinylated miRNA. When cen-
tered sites were considered, allowing for GU wobble andup to one mismatch, we could account for substantially
more of the significantly enriched targets (mean 82.7%,
standard deviation 7.5%), suggesting that centered sites
could indeed bind mRNAs on a large scale.
Shin et al. [21] reported that centered site matches
were significantly associated with repression only if they
involved perfect Watson-Crick base-pairing. However,
we postulated that these sites might still be able to medi-
ate interactions if they included GU pairs or a mismatch.
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only Watson-Crick binding (centered-WC) or with GU
wobble (centered-GU) and with either no mismatches
(0MM) or with one mismatch (1MM) (that is, any base
pair other than C-G, A-U or G-U). Centered sites with
only Watson-Crick matches accounted for only a small
proportion of the significantly enriched transcripts (0.5%
and 6.6% for 0MM and 1MM sites, respectively), but a
much greater proportion of these putative target tran-
scripts contained centered-GU sites (12.5% and 72%);o
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ple size, we repeated our analysis using all transcripts
enriched in our pull-downs. For every site type, we again
saw a significant over-representation of transcripts with
a site amongst the putative target set, with the strongest
enrichment being seen for the centered sites with perfect
Watson-Crick pairing (Figure S7A in Additional file 8).
These results suggest that the centered sites of the
miRNA can mediate interactions with transcripts even
in the absence of seed sites.Centered sites can mediate interactions in the coding
sequence and 3′UTR of mRNAs
To investigate whether the location of the putative
miRNA binding sites affected whether or not a tran-
script would be enriched in the pull-down, we fitted a
logistic regression model for enrichment status, includ-
ing the counts of each type of site within different tran-
script regions as covariates (see Materials and methods).
This model was highly significant (P < 0.0001), although
it only explains a small fraction of the variance (Nagelk-
erke r2 = 0.04). As expected, the more seed sites there
were in a transcript’s 3′ UTR, the more likely it was to
be significantly enriched in the pull-down (Figure 4B,
left-most yellow bar). Interestingly, all types of centered
sites in the 3′ UTR were significantly associated with en-
richment status (Figure 4B, yellow bars). Consistent with
recent literature [6,20,29-32], most site types were sig-
nificant in the coding sequence (CDS) too (Figure 4B,
orange bars), although the effects were strongest in
the 3′ UTR in most cases. Curiously, when we con-
trolled for the length of the regions by fitting the logistic
regression with site densities as covariates, the coeffi-
cient estimates were greater for the CDS than the 3′
UTR (Figure 4C) for all site types. It may be that while
miRNAs are more likely to target UTRs with more sites,
there is a trade-off between the number and accessibility
of sites (reflected by site density), and site accessibility
is more important in the UTR than the CDS, perhaps
because of mRNA secondary structure. Interestingly,
though, the r2 was much lower for this model (0.008)
than when we fit site counts as covariates, although it
was still significant (P < 0.0001). To ensure that the lo-
gistic regression was not being confounded by the inclu-
sion of multiple transcripts bound by the same probe
(which are not independent of one another), we ran the
analysis again including only the canonical isoform of
each gene. This did not substantially change the results
(P < 0.0001, Nagelkerke r2 = 0.05 for site count; P <
0.0001, Nagelkerke r2 = 0.009 for site density; Figures
S7B,C in Additional file 8). We conclude that centered
sites can mediate interactions both within and outside
the 3′ UTR, although 3′ UTR interactions are moreimportant, as has previously been shown for seed sites
[33-35].
Similarity between target sets of canonical miRNAs and
their isomiRs
If centered sites are indeed mediating biologically rele-
vant interactions, then we would expect this to be
reflected in the pattern of transcripts that are enriched
in the biotin pull-down of both a canonical miRNA and
its isomiR.
Since the isomiRs have different seed sites from their
canonical partners but share overlapping centered sites,
we might expect the transcripts they target in common
(Figure 5) to be enriched for centered sites relative to
the transcripts targeted by only one or the other. Con-
versely, since miR-10a and miR-10b have the same seed
but different centered sites, the transcripts targeted by
both miRNAs might be enriched for seeds compared to
transcripts targeted by only miR-10a or miR-10b. For
this analysis, we excluded transcripts with multiple dif-
ferent types of sites for the same miRNA. Although this
approach lost some statistical power through the large
reduction of transcripts, we still found statistical support
(P ≤ 0.05) for each of the five comparisons (miR-10a
versus miR-10b; miR-10a versus miR-10a-iso; miR-10b
versus miR-10b-iso; miR-182 versus miR-182-iso; miR-
17-5p versus miR-17-5p-iso), and a total of 14/20 of the
observed enrichments confirmed our hypothesis (Table
S4 in Additional file 1). For example, the transcripts that
were enriched in the pull-downs of both miR-182 and
miR-182-iso were significantly more likely to have a cen-
tered site compared to the set enriched in only the miR-
182 pull-down (one-sided FET; OR = 1.45; 95% CI 1.04
to 2.04; P = 1.9 × 10-2) or in only the miR-182-iso pull-
down (OR = 2.07; 95% CI 1.54 to 2.8; P = 9.4 × 10-7).
There was also a significant over-representation of tran-
scripts with a seed site amongst the transcripts targeted
by miR-10a and miR-10b compared to those targeted
by only miR-10a (OR = 2.13; 95% CI 1.3 to 3.6; P = 2.0 ×
10-3). These results again support the hypothesis that
centered sites in mRNAs can mediate interactions with
miRNAs, although we cannot rule out the possibility
that the transcripts pulled down by multiple miRNAs
were being targeted by non-canonical sites other than
the centered site.
Centered sites are enriched in AGO-bound regions
If centered sites are truly mediating miRNA-mRNA in-
teractions, and are not an artifact of the experimental
approach used here, then we would expect such sites to
be enriched in regions of mRNAs bound by RISC and
endogenous miRNAs. In 2012, Loeb et al. [20] used dif-
ferential AGO2 HITS-CLIP to profile murine primary T
cells that were either miR-155 wild-type or were miR-
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http://genomebiology.com/2014/15/3/R51155 deficient due to genetic knock out. Due to the high
number of biological replicates (12 of each condition),
the authors were able to robustly define 14,634 AGO2
bound regions, with 398 of these differentially detected
only in wild type compared to knock out (adjusted
P < 0.05), and therefore likely to be directly mediated
by miR-155. We exploited these data to look for the
frequency and location of imperfect centered sites and
seed sites relative to the peak. We first confirmed that
seed sites were significantly enriched in differentially
detected AGO peaks compared to AGO peaks that
were unchanged between wild type and knock out (FET,P ≈ 8.07 × 10-32, n = 111), and were significantly skewed
towards the center of the predicted peak (excess kur-
tosis = 7.34; Figure 5D). We also observed enrichment
and kurtosis for imperfect centered sites (FET, P ≈
5.19 × 10-3, n = 29; excess kurtosis = 3.50; Figure 5E),
although these sites were less frequent than seed sites.
The overlap between seed and centered sites (n = 6) was
not significantly different to what would be expected
by chance (FET, P = 0.7887). Together these results
suggest that imperfect centered sites can mediate en-
dogenous miRNA-mRNA interactions independently of
seed sites.
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Figure 6 Centered sites can repress gene expression. (A) Four imperfect centered binding sites for miR-17-5p (left column) and eight for
miR-27a (right columns) were tested via luciferase assay. Vertical line, perfect Watson-Crick matches; colon, GU wobble sites; shaded bases, regions
outside of the central zone (nucleotides 3 to 15) that may participate in binding; red text, mismatches between the miRNA and its target in the
central zone. Note that no other binding sites of any type were predicted within these mRNAs. (B) Mean luciferase activity relative to negative
controls from the empty plasmid (pMIR) or pMIR containing one of the imperfect binding sites described above in the 3′ UTR. Asterisks indicate
significant reduction in luciferase activity (one-sided t-test; P < 0.05), error bars represent standard error of the mean over three replicates. (C,D) A
hybrid AGO2 immunoprecipitation/biotin pull-down was performed as in Figure 2F, and qRT-PCR was used to detect mRNAs confirmed to be
targets of miR-17-5p (C) and miR-27a (D) above. Numbering on the x-axis refers to the samples described in Figure 2F. All targets were found to
be significantly enriched in the AGO2-enriched fraction (*P ≤ 0.05, **P < 0.01, ***P < 0.001). (E,F) Analysis of luciferase expression levels by qRT-PCR
found that only one out of three imperfect centered sites for miR17-5p (E) and one out of four sites for miR-27a (F) showed significantly reduced
luciferase mRNA levels (P < 0.05, indicated by asterisks), indicating that most interactions that result in reduced protein are due to translational
inhibition and not mRNA degradation.
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through translational inhibition
Although our results suggest that imperfect centered
sites can direct RISC to mRNAs, it does not necessarily
follow that those sites can mediate repression of gene
expression. To address this specific question, we ran-
domly selected 12 genes that were both significantly
enriched in the biotin pull-down experiment and had
only a single centered miRNA binding site in the tran-
script, for testing via luciferase assay (Figure 6). All but
one of the centered sites included GU wobble, and 9 of
them also had a single mismatch between the miRNA
and the mRNA. We validated two of three centered sites
with no mismatch, and eight of nine centered sites with
one mismatch. The rate of validation seen here (79%) is
much higher than previously reported validation rates
based on bioinformatics predictions alone (39%) [8], and
again supports the robustness and utility of the biotin
pull-down approach. These results demonstrate that
even without perfect complementarity, centered sites
can mediate mRNA repression in mammalian systems.
To ensure that the centered sites were mediating
their function through RISC, we repeated the hybrid
AGO immune-precipitation/biotin pull-down approach
(Figure 2F) to look for enrichment of these centered
sites in AGO2-RISC. For both miR-17-5p imperfect cen-
tered sites (Figure 6C), and miR-27a imperfect centered
sites (Figure 6D), all targets were found to be signifi-
cantly enriched (P ≤ 0.05) in the AGO2 enriched fraction
compared to the input mRNA population, demonstrat-
ing that interactions between an imperfect centered site
and its target mRNA were mediated through RISC.
Finally, to determine whether imperfect centered sites
mediate mRNA destabilization or translational inhib-
ition, we repeated the luciferase assays described above
(Figure 6B), and measured the level of luciferase gene
mRNA via qRT-PCR. Changes in the mRNA levels be-
tween the control mimic and the test miRNA would in-
dicate mRNA destabilization, whereas no changes in the
mRNA levels would indicate translational inhibition.
Only one out of four sites for miR17-5p (Figure 6E) andone out of five sites for miR-27a (Figure 6F) showed sig-
nificant (P < 0.05) reduction of mRNA levels, indicating
that most interactions that result in reduced protein are
due to translational inhibition rather than mRNA degrad-
ation, although both types of regulation are possible.
These experiments together provide substantial experi-
mental evidence that imperfect centered sites are common
targets of miRNAs, and mediate functional interactions.
The biotin pull-down technique is slightly biased against
seed sites
A consideration for interpreting the results derived from
this protocol is that the biotin tag on the synthetic
miRNA duplexes may prevent their 3′ ends from bind-
ing to the PAZ domain of Ago [2]. This may allow
biotin-labeled miRNAs to interact more easily with tar-
get mRNAs and alleviate the requirement for 5′ end
binding. The method may therefore be biased towards
detecting interactions that are not mediated by the ca-
nonical seed.
To explore the potential bias of this method in the af-
finity for different types of target sites, we used bio-layer
interferometry (BLI) to detect the rates of association
and disassociation of RISC with various types of binding
sites (Figure 7A). The higher the ratio of association/dis-
association is, the stronger the affinity of RISC to a bind-
ing site will be. Biotin miR-182-5p RISC was generated
by transfecting MDA-MD-231 cells with biotin-labeled
miR-182-5p duplexes, whilst native miR-182-5p RISC
was generated by inducing expression of miR-182-5p by
adding doxycycline to a previously generated and vali-
dated inducible cell line [36]. RNA oligos containing
seed, centered, and 3′ binding sites (Figure 7B) were la-
beled with biotin and bound to the streptavidin-coated
BLI sensors, blocked in free biotin blocking buffer, and
used to probe biotin RISC or native RISC. The 'no oligo'
control confirmed the effectiveness of this blocking and
confirmed that there was no association between the bio-
tin RISC and the BLI sensors after blocking (Figure 7C).
The rate constants for association and disassociation were
calculated independently for four independent biological
AC
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Figure 7 Biotin RISC differs only slightly from native RISC in affinity for centered sites. (A) Schematic diagram showing the bio-layer
interferometry (BLI) experimental design. Cells were either transfected with biotinylated miR-182-5p or induced to over-express miR-182-5p, and
RISC complexes containing these miRNAs were affinity purified. The two RISC solutions were used in parallel BLI runs to detect association and
disassociation with RNA oligos containing the binding sites. The arrows indicate the sequential immersion of the sensors in a row. Lane 1, no
lysate; lane 2, no oligo; lane 3, miR-182-5p 3 prime binding site; lane 4, miR-182-5p imperfect centered site with GU wobble; lane 5, miR-182-5p
imperfect centered site; lane 6, miR-182-5p perfect centered site; lane 7, miR-182-5p seed site. (B) The binding between miR-182-5p and the RNA
oligo is illustrated. The miRNA is depicted on the top strand, and the binding site in the oligo on the bottom strand. Perfect Watson-Crick
matches are indicated with the vertical line, and GU wobble sites by a colon. (C) A representative association/disassociation curve from the BLI
showing the wavelength interference (nm) versus time. The dashed line indicates the time at which the BLI sensors were removed from the RISC
solution and transferred to buffer. (D) Rate constants for association were calculated independently from four biological replicates, and plotted
separated for biotin RISC (B) and native RISC (N) across all five binding sites. Error bars represent standard error of the mean (sem). (E) Rate
constants for disassociation were calculated and plotted as for (D). Error bars represent standard error of the mean (sem). (F) The normalized
affinity for each site type was calculated by dividing the association rate constant by the disassociation rate constant, and normalizing all site
types to the ratio for the seed site. This shows that, with the exception of 3' sites, the relative affinities between biotin RISC and native RISC are
essentially equivalent.
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RISC (Figure 7D,E).
As expected, the association rates for seed sites are the
highest of all sites, and dramatically higher than for 3'
sites. Although we find no statistically significant differ-
ence between native RISC and biotin RISC for any inter-
action, we did observe a trend for native RISC to
associate with all binding sites faster than biotin RISC
(Figure 7D) and for native RISC to disassociate slower
(Figure 7E) than biotin RISC. The only exceptions were
imperfect-GU sites, which showed the same dissociation
rate for native and biotin RISC, and 3' sites, which were
much higher for native risk (approaching statistical sig-
nificance, P ≈ 0.06). Thus, all but 3' site-mediated inter-
actions are stronger in the absence of the biotin tag.
Overall affinities (as measured by the ratio of associ-
ation/disassociation) are very similar between biotin and
native RISC for all types of sites (Figure 7F), but it is
worth noting that the protocol used here could be af-
fected by the higher disassociation rates of the seed sites.
This is because in the biotin pull-down, unlike CLIP-
based methods, the interactions are not fixed in the cell
before isolation, so they can disassociate, and we would
expect biotin RISC to disassociate more quickly from
seed sites than native RISC. Together, this could result
in a reduced affinity, transcriptome-wide, for seed sites
in our biotin pull-down compared to what would be ex-
pected for native RISC-based protocols. We see some
evidence for this in the slightly lower proportion of tar-
gets that are accounted for only by seed sites in our
study compared to other studies - approximately 41% of
our biotin pull-down targets can be explained by a seed
site, versus 50% for PAR-CLIP data [12] (although we
note that this 50% refers to a seed match to any of the
top 100 expressed miRNAs). We interpret these results
to mean that the biotin pull-down has a slight bias away
from seed sites rather than any particular bias towards
centered sites. In our data, this probably manifests as a
lower percentage of seed sites, but importantly, the affin-
ity between native RISC or biotin RISC to centered sites
is essentially equivalent and therefore our conclusions
regarding the biological relevance of these sites are un-
likely to be an artifact of the protocol used, although the
prevalence of these interactions may be slightly inflated
by the bias away from seed sites.
Discussion
In order to understand the function of a particular
miRNA, it is essential to know its targets. All methods
for elucidating these have weaknesses, including the bio-
tin pull-down approach described previously [17,18] and
used here. We chose this protocol because it is not con-
founded by secondary effects (unlike microarray-based
miRNA modulation studies) and because it is moresensitive for detecting differences between two closely
related miRNAs than other whole-transcriptome ap-
proaches such as HITS-CLIP. The inclusion of stringent
bead-blocking and washing steps has allowed us to sub-
stantially increase the specificity and dynamic range of
the assay; the protocol described by Orom et al. [18]
achieved a maximum fold-change of 4, while the tran-
scripts in our biotin pull-downs were enriched up to
eight-fold (Figure S1B in Additional file 2). However, we
should anticipate that a proportion of transcripts de-
tected as significantly enriched in our biotin pull-down
may still not interact with the miRNA of interest. This
type of false positive could occur through non-specific
interaction with the magnetic streptavidin beads, or by
association with endogenous biotin rather than with a
biotinylated miRNA. Several lines of evidence suggest
that this type of false positive is reasonably uncommon:
(i) up to 90% of significantly enriched transcripts contain
a predicted binding site (average 82.7%); (ii) of the
remaining annotated (HUGO) transcripts without pre-
dicted binding sites, almost 40% were shown to contain
novel transcriptional events with predicted bindings sites
within them; and (iii) the vast majority of miRNA bind-
ing sites tested in luciferase assays were validated
(Figures 2B and 6B) and were enriched in AGO2 con-
taining silencing complexes (Figures 2G,H and 6C,D),
although this was a small number of sites.
A second class of false positives would be those inter-
actions that genuinely involve the biotinylated miRNAs
but that do not occur endogenously in cells. This set is
more difficult to define in the absence of a large cohort
of true positives - even the ‘gold standard’ luciferase as-
says involve exogenous plasmids tested with exogenous
miRNA mimics or inhibitors. While these assays can
show that it is possible for a specific miRNA to interact
with a specific binding site, they cannot prove that a spe-
cific miRNA interacts with a specific binding site en-
dogenously. Factors such as RNA secondary structure,
differences in the cellular concentration of miRNA and
other miRNA binding factors, and secondary effects of
miRNA modulation can all confound the interpretation
of what are 'true targets' of a given miRNA. Just as pre-
cise false positive rates are difficult to calculate, the
false-negative rates are equally intractable. An accurate
assessment of the false negative rate would require a
very large number of luciferase assays (if these are con-
sidered the gold standard) to establish a true positive set,
and then ask how many of these were missed by the bio-
tin pull-down approach. Such an experiment is impracti-
cal and expensive. However, like any difficult biological
problem, orthogonal validation and careful interpret-
ation are critical, and we were encouraged that miRNA
targets inferred from all high-throughput methods and
luciferase assays were significantly more likely to be
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in Additional file 1), and that the overlap seen between
our results and those from the miR-17-5p over-expression
experiments is similar to that observed between the latter
and AGO2 immuno-precipitation datasets [34,37].
Although we did not find any statistically significant
differences between native RISC and biotin RISC in their
affinities to seed or centered sites, the trend did suggest
that biotin-labeled miRNAs were slightly less able to de-
tect seed sites than native miRNAs, which could result
in a relative increase in the proportion of centered sites
in our data. This could explain the drop from 50% seed
sites in the PAR-CLIP data [12] to 41% in our study.
However, the large variability amongst individual miR-
NAs is likely to be a substantial contributing factor - we
observed a standard deviation of 10.1% in the proportion
of transcripts containing seed sites. Similarly, although
imperfect centered sites were significantly enriched in
endogenous AGO2 clusters mediated by miR-155 [20],
they were almost four times less frequent than seed sites
(7.3% versus 27.9%, respectively). This difference is likely
to be a combination of the bias of the biotin pull-down
approach, unexplored biases in the HITS-CLIP detection
(including cluster stringency and bioinformatic inference
of sites), and genuine biological differences in the target-
ing profiles of different RISC species. Regardless, while
any bias towards site types should be considered when
interpreting their relative importance, it is clear that im-
perfect centered sites account for a substantial fraction
of the total interactions between the miRNA and mRNA
populations.
We have used the biotin pull-down technique to inves-
tigate associations between the number of predicted
miRNA-binding sites and a transcript’s enrichment in
the pull-down (Figure 4). These associations were stron-
ger for site counts in the 3′ UTR than in the CDS, con-
sistent with previous reports that 3′ UTR seed matches
are more important for mediating interactions [33-35]. It
is striking that the number and density of centered sites,
and not just of seed sites, was also significantly associ-
ated with enrichment in the pull-down. The hypothesis
that centered sites mediate many interactions is also
supported by the considerable differences between the
target sets of miR-10a and miR-10b (Figure 5A), which
share the same seed but have different centered sites, al-
though it is possible that some differences are accounted
for by 3′ complementary sites.
Shin et al. [21] reported that 'perfect 11-mer matches
starting at miRNA positions 3, 4 and 5 were each signifi-
cantly associated with repression' in over-expression
studies, but that 11-mer matches with single mismatches
or GU wobbles were not. However, microarray based-
assays that rely on changes in the expression levels of
target mRNAs will not identify translationally repressedmRNAs, which have been shown to be the primary dir-
ect effect of miRNAs [38]. Results from our luciferase
assays, which detect miRNA effects at both the mRNA
and protein levels, suggest that imperfect centered sites
are bona fide miRNA-binding sites that can elicit repres-
sion. Given that only a small proportion of the imperfect
centered sites result in mRNA destabilization (Figure 6E,F),
this would explain why these sites failed to validate in
microarray-based studies, but did validate here in luciferase
assays (Figure 6B).
Further experimental work on a larger number of sites
would be required to elucidate precisely the minimal
length and maximum number of mismatches required
for centered site-mediated interactions. Regardless, the
finding that both perfect and imperfect centered sites
can repress gene expression has significant implications
for understanding miRNA-controlled genetic networks,
as the prevalence of centered sites in the mammalian
transcriptome dramatically increases the connectivity
and complexity of the networks. It may also explain the
evolutionary conservation of regions outside of the seed
site [7,21], although we cannot formally exclude the
hypothesis that these regions are conserved due to pro-
cesses related to miRNA biogenesis. Further experimen-
tal work would also be required to compare the efficacy
of seed versus centered sites. Although the percentage
reduction in luciferase activity shown here (Figure 6B) is
comparable with that seen in other studies for seed sites
[8], a thorough comparison would require thousands of
luciferase assays with accompanying RNAseq and prote-
omics data.
While centered sites will clearly need to be factored
into systems biology models of genetic regulation, it is
currently unclear how much (if any) predictive power
would be added to target prediction algorithms by the
inclusion of imperfect centered sites. It was beyond the
scope of this study to develop a prediction model in-
corporating centered site information, although it seems
likely that the high frequency of these sites in the tran-
scriptome would require that additional information
such as evolutionary conservation and site accessibility/
RNA secondary structure be incorporated to reduce the
rate of false positive predictions, as is the case for seed
sites. Despite the conceptual simplicity of looking for re-
gions of complementarity, miRNA target prediction suf-
fers from both a lack of specificity (due to the short
binding sites), and a lack of sensitivity due to the exclu-
sion of known binding modalities to increase prediction
accuracy. This is analogous to the problems suffered
by transcription factor binding prediction software, and
was a significant driver in the quest for unbiased experi-
mental methods such as ChIP-seq. We believe that
the biotin pull-down methodology is complementary to
other transcriptome-wide tools such as HITS-CLIP to
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binding modes.
While we have demonstrated here that centered sites
are direct targets of miRNAs that result in molecular re-
pression of the target, the larger relationship between
targeting and functional repression remains an open
question. In biological networks, mRNAs can be insu-
lated from the effects of miRNAs by simply expressing
more copies of the mRNA [8], so whilst individual tran-
scripts are still targeted and repressed, the overall pro-
tein levels may not change. How many of the targets
identified here are functionally repressed versus molecu-
larly repressed is currently unknown, but this is not a
weakness of the biotin pull-down (or indeed, a weakness
of any other transcriptome-wide method). Instead, this
presents us with the interaction data necessary to model
properly the outcomes of biological networks in different
cell types or tissues with different mRNA expression
levels. It will be the combination of these transcriptomic
methods with proteomics data that will enable the next
leap in understanding.
Conclusions
We used a biotin pull-down method to determine the
direct targets of 10 human miRNAs, and found that
imperfect centered sites are common mediators of
miRNA-mRNA interactions. These sites can repress
mRNA activity, typically through translational repres-
sion, but further work is needed to establish their func-
tional importance relative to seed sites. Our findings
may explain the evolutionary conservation of the central
region of miRNAs, and they have important implications
for studying miRNA-regulated genetic networks, and for
interpreting putative disease-causing variants that do not
alter protein sequence but that may fall inside miRNA
binding sites.
Materials and methods
Biotin pull-downs, microarray hybridizations and
sequencing
We optimized the biotin pull-down method of Orom
et al. [18] to improve RNA yield and dynamic range.
Briefly, 200 pmoles of synthetic biotin-labeled miRNA
duplexes (Table S1 in Additional file 1) were transfected
into 4 × 106 HEK293T cells using HiPerFect Transfection
Reagent (QIAGEN, Melbourne, VIC, Australia). Cells
were harvested after 24 hours, and lysed in hypotonic
lysis buffer (10 mM KCl, 1.5 mM MgCl2,10 mM Tris-Cl
pH 7.5, 5 mM DTT, 0.5% NP-40, 60U/ML SUPERase•In
(Ambion, Austin, TX, USA) and 1X Complete Mini pro-
tease inhibitor (Roche, Brisbane, QLD, Australia)). Cell
debris was cleared by centrifugation (≥10,000 g at 4°C
for 2 minutes). The supernatant was transferred to a
clean tube, and NaCl was added to a final concentrationof 1 M. myOne C1 Dynabeads (25 μl; Invitrogen) were
pre-blocked with 1 μg/μl bovine serum albumin and
1 μg/μl yeast tRNA (Invitrogen), and incubated with the
supernatant for 30 minutes at room temperature. Beads
were then washed with hypotonic lysis buffer and 1 M
NaCl before RNA extraction using an RNeasy Kit
(QIAGEN) according to the manufacturer’s instructions.
Pull-downs were conducted in duplicate or triplicate for
each miRNA, and 50 ng of the captured mRNAs per
sample were amplified and labeled using the Illumina
TotalPrep RNA Amplification Kit (Invitrogen) as per the
manufacturer’s instructions. Samples were profiled on
Illumina Human HT-12 chips along with control RNA
from mock-transfected cells to which no miRNA had
been introduced. In parallel, RNA extracted from the
miR-17-5p pull-down was used in RNAseq library con-
struction as previously described [39] and 50 bp tags were
generated on the Applied Biosystems SOLiD (Melbourne,
VIC, Australia). These were mapped to the human genome
(GRCh37) using the default parameters of the X-MATE
pipeline [40]; 70,714,217 of the 101,137,997 tags aligned to
GRCh37 (70%).
Hybrid AGO immuno-precipitations and biotin pull-downs
We transfected cells with either synthetic biotinylated
miRNA duplexes or synthetic single-stranded biotinyl-
ated miRNAs and lysed the cells as described above.
After clearing the cell lysate, we harvested 10 μl to use
as the input RNA sample. We then used a Dynabeads
Protein G Immunoprecipitation Kit (Invitrogen) com-
bined with a ChIP grade mouse monoclonal antibody to
AGO2 (ab57113, Abcam, Cambridge, MA, USA) to
perform the AGO enrichments according to the manu-
facturers’ instructions. Briefly, 50 μl of beads per precipi-
tation were washed prior to incubation with 10 μg of
antibody at room temperature for 10 minutes. Cell lysate
was added to the bead-antibody complexes, and incu-
bated for 10 minutes at room temperature. The super-
natant from this step was saved as the AGO2-depleted
fraction, and the beads were kept as the AGO2-enriched
fraction. The beads were washed three times in 200 μl of
wash buffer, prior to elution in 30 μl of elution buffer.
We then completed the biotin pull-down protocol on
both the AGO2-enriched fractions and the AGO2-
depleted fractions, as described above.
Primary analysis of microarray data
Statistical tests were conducted in R. Microarray data
were normalized using the lumi package [41], by apply-
ing background adjustment, variance-stabilizing trans-
formation [42] and robust spline normalization [43]
successively. Hierarchical clustering of normalized data
(Additional file 9) showed that replicates tended to clus-
ter together and that the samples from the pull-down of
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corresponding isomiR pull-down, as expected given the
similarity in their sequences. One miR-10b pull-down
sample was excluded because it did not cluster with the
other replicates. Microarray probes that detected expres-
sion above background (detection P-value <0.01) in all
control samples were retained (n = 12,008). The lmFit
and eBayes functions in the limma package [44] were
used to test for differences in RNA abundance ('differen-
tial expression') between the pull-down samples and the
controls. The FDR was calculated to account for multiple
testing [45]. Probes that met the 5% FDR threshold
(for one-sided tests) were considered significantly enriched
in the pull-down. The transcripts (EnsEMBL V62) to
which they matched exactly were considered putative tar-
gets of that miRNA.
Analysis of published data on miRNA-mRNA interactions
These lists of targets were compared to results from
published datasets, considering miRNA-target interac-
tions that had been demonstrated by luciferase assays
(Table S3 in Additional file 1) and by various high-
throughput methods. Table S5 in Additional file 1 sum-
marizes our analysis of the latter. To test whether the
biotin pull-down targets were enriched in the target list
from another study, a FET was applied to ask whether
the biotin pull-down targets were more likely than non-
targets to be in the target list from another study. Unless
otherwise stated, reported one-sided P-values are from
an upper-tailed test, and an OR >1 indicates that genes/
transcripts/probes that are targets in our biotin pull-
down are more enriched amongst the targets identified
in the experiment being examined than those that are
not targets in the pull-down.
Unless otherwise stated, reported one-sided P-values
are from an upper-tailed test, which evaluates the hy-
pothesis that the odds ratio, w=xy=z , is greater than 1. Am-
biguous genes/transcripts (those that were detected both
by a probe that was significantly enriched and by a probe
that was not) were excluded unless otherwise specified.
Kolmogorov-Smirnov tests were conducted to compare
the distribution of fold-change (expression in biotin
pull-down/control) between canonical transcript targets
inferred from published experiments and all other ca-
nonical transcripts (the canonical EnsEMBL transcript is
the longest produced from a gene).
In silico prediction of miRNA-binding sites
TargetScanS [1] was run on all EnsEMBL transcripts to
find seed matches to the miRNAs of interest. A Perl
script was also written to count matches to the centered
site (11 bp sequence starting at position 3, 4 or 5 of the
miRNA). For centered sites, we allowed GU wobble andup to one mismatch (MM) in the middle of the site. We
divided the centered sites into four classes (WC 0MM,
WC 1MM, GU 0MM, GU 1MM) for all analyses except
those of the combined target sets of isomiRs and their ca-
nonical partners, in which we pooled all classes together.
Statistical analysis of predicted binding sites and
enrichment status
A FET was applied to ask whether transcripts containing
at least one predicted binding site of a particular type
were more likely than those with no site to be unam-
biguously classified as targets in the pull-down.
To investigate whether the location of the putative
miRNA binding sites affected enrichment status, the fol-
lowing logistic regression model was fitted on the com-
bined data from all pull-downs:
logit pi;m
 
¼ ln pi;m
1−pi;m
 !
¼ β0 þ β1;1x1;1;m:i þ β2;1x2;1;m:i þ…
þ βj;kxj;k;m:i
where pi,m is the probability that the probe detecting
transcript i is significantly enriched in the pull-down of
miRNA m; xa,b,m,i is the number of miR-m sites of type
a in region b of transcript i (for example, miR-17-5p
seed sites in the 3′ UTR); βa,b is the coefficient (or
weight) corresponding to that count and β0 is some con-
stant. A value of βa,b significantly greater than zero
would indicate that, as the number of sites of type a in
region b of a transcript increases, so too does the prob-
ability that the transcript is detected as significantly
enriched in the pull-down. All coding transcripts with
unambiguous enrichment status were included.
Luciferase assays
Luciferase assays were carried out as previously de-
scribed [8]. Briefly, complementary oligonucleotides cor-
responding to 54 nucleotides surrounding the miRNA
binding site were annealed before being cloned into the
SpeI and HindIII sites of pMIR-REPORT Luciferase
(Ambion). A list of all oligonucleotides used is available
in Table S6 in Additional file 1. All constructs were veri-
fied by capillary sequencing. HEK293T cells were co-
transfected with 50 ng of a pMIR-REPORT Luciferase
construct, 50 ng of pMIR-REPORT β-galactosidase
(Ambion) and 10 nM of the appropriate mirVana
miRNA mimic (Ambion/Life Technologies). After trans-
fection, cells were incubated for 48 hours prior to
harvesting. Luciferase activity was assayed using the
Luciferase Assay System (Promega, Sydney, NSW,
Australia), and detected on a Wallac 1420 luminometer
(Perkin Elmer, Waltham, MA, USA). Transfection
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the β-Galactosidase Enzyme Assay System (Promega,
Sydney, NSW, Australia), and detected on a PowerWave
XS spectrophotometer (BioTek, Winooski, VT, USA).
Quantitative RT-PCR
Primers used to determine whether transcripts were de-
graded after miRNA transfection are listed in Table S7
in Additional file 1. Cells were either mock-transfected,
or transfected with biotinylated miRNAs as described in
the Materials and methods section. RNA was purified
from cell pellets using an RNeasy Mini Kit (QIAGEN).
RNA integrity was assessed using an Agilent Bioanalyzer
2100, cDNA synthesis was carried out using random
hexamer primers and SuperScript III (Invitrogen). qRT-
PCR was performed using SYBR green PCR master-mix
(Applied Biosystems) on an Applied Biosystems ViiA™ 7
Real time PCR system. Expression levels were calculated
relative to those in the mock-transfected cells.
Bio-layer interferometry
The generation and validation of the MDA-MB-231
miR-182-5p inducible cell line has been previously de-
scribed [36]. miRNA expression was induced by the
addition of 1 μg/ml doxycycline. Biotin-labeled miRNA
duplexes were transfected into MDA-MB-231 cells
using Dharmafect 4 (Thermo Fischer, Melbourne, VIC,
Australia) according to the manufacturer’s instructions
for this cell line. All cells were incubated in 5% CO2 for
48 hours prior to harvesting. RISC affinity purification
was performed as previously described [46] with the
following modifications: (i) the lysis buffer used was
10 mM Tris pH7.5 (Ambion), 10 mM KCl (Ambion),
1.5 mM MgCl2 (Ambion), 0.5 mM DTT (Invitrogen),
0.5% NP40 (Sigma Aldrich, Sydney, NSW, Australia),
and 1X EDTA-free Complete protease inhibitor (Roche);
(ii) cell lysates were cleared by centrifugation at 16,000 g
for 30 minutes at 4°C. The miR-182-5p capture oligo
and all binding site oligo sequences are shown in Table
S8 in Additional file 1. Association and disassociation
profiles were generated using the Octet Red (Forte Bio,
Menlo Park, CA, USA) and streptavidin biosensors
(Forte Bio) using the following parameters: lysis buffer
for 60 seconds; RNA oligo for 10 minutes; saturated bio-
tin (Sigma Aldrich) solution for 10 minutes; lysis buffer
for 60 seconds; RISC solution for 10 minutes (associ-
ation); lysis buffer for 10 minutes (disassociation). Wells
were kept at 30°C, and rotated at 1,000 rpm to ensure a
homogenous mix.
Accession numbers
Data used in this manuscript are available from the Gene
Expression Omnibus (GEO) under accession numbers
GSE29101 (miR-10 family and mock transfection microarraydata), GSE38593 (miR-182 microarray data), GSE40406
(miR-424 and miR-199a microarray data), and GSE55059
(all remaining microarray and sequencing data).
Additional files
Additional file 1: Table S1. Sequences of the biotinylated miRNA
duplexes. Table S2. miRNA-target interactions demonstrated by reporter
assay [8,17,47-112]. Table S3. Results from Fisher’s exact tests for over-
representation of genes implicated as targets via miRNA over-expression
experiments, PAR-CLIP or luciferase assays amongst the set of genes
significantly enriched in the pull-downs (5% FDR). Table S4. Results from
Fisher’s exact tests examining enrichment of transcripts with a certain site
type amongst transcripts targeted by two related miRNAs. Table S5.
Summary of analysis of published studies. Table S6. Primers used for
construction of pMIR-REPORT luciferase assay constructs. Table S7.
Primers used for qRT-PCR analysis of mRNAs after transient transfection
with biotinylated miRNA-duplexes. Table S8. Oligos used for RISC affinity
purification and bio-layer interferometry.
Additional file 2: Figure S1. Biotin pull-downs enrich for predicted
and previously validated targets of miRNAs. (A) Left: two different miRNA
duplexes, hsa-miR-424-3p (blue) and hsa-miR-199b-5p (red), were
transfected into HEK293T cells, independently replicated three times.
Total RNA samples (dotted lines) and pull-down miRNA enrichments
(solid lines) were assayed by microarray, and clustered using the plotSam-
pleRelations function of lumi. There is a very close relationship between
the total RNA samples, even though they have been transfected with
two different miRNAs with very different targets. Right: correlation of
HEK293T control RNA transfected with either miR-424-3p or miR-199b-5p
miRNAs. This demonstrates that there is very little effect of either duplex
in this cell line, and that there is no major disruption of the underlying
genetic networks upon transfection at this concentration. (B,C) Volcano
plots showing the significance of the difference in expression between
the indicated pull-down and the mock-transfected control, for all
transcripts expressed in control cells. Targets predicted by TargetScan
or validated previously via luciferase assay are indicated by orange and
green dots, respectively. (B) A comparison between miR-10a biotin
pull-down in this study (left) and by Ørom et al. [17] (right). P-values
for the enrichment of luciferase validated targets or TargetScan predicted
targets are indicated. Red dashed lines indicated the significance
threshold and the fold-change threshold used in this study. For the
pull-downs performed by Ørom et al., no enrichment of known or
predicted targets was observed. (C) Volcano plots for all 10 miRNAs/
isomiRs used in this study.
Additional file 3: Figure S2. Distribution of log2 fold-change values for
the miRNAs/isomiRs used in this study. Canonical miRNAs are plotted as
solid lines. IsomiRs are plotted as dashed lines.
Additional file 4: Figure S3. Targets identified through PAR-CLIP
show greater enrichment in the biotin pull-down. Cumulative distribution
of log fold-change in the biotin pull-down for transcripts identified as
targets via PAR-CLIP [12] or not. Red, canonical transcripts containing
at least one CLIP cluster (Table S5 in Additional file 1); black, all other
canonical transcripts; p, one-sided P-value from Kolmogorov-Smirnov
test for a difference in distributions.
Additional file 5: Figure S4. RT-PCR of genes previously confirmed by
luciferase assay. The bar plot indicates the expression of the indicated gene
in HEK293T cells transfected with miR-17-5p relative to mock-transfected
cells. These genes had previously been shown to be targeted by miR-17-5p
in luciferase assays. Error bars indicate 95% confidence intervals calculated
over three biological replicates. Asterisks indicate significantly reduced
expression compared to mock-transfected cells (one-sided t-test).
Additional file 6: Figure S5. Distribution of binding sites in miRNA
transcripts. Frequency histograms showing the distribution of the
number of each site type per transcript, for each of the 10 miRNAs
used in this study (Table 1).
Additional file 7: Figure S6. Proportion of transcripts with miRNA
binding sites. Proportion of transcripts with a predicted binding site for
Martin et al. Genome Biology 2014, 15:R51 Page 19 of 22
http://genomebiology.com/2014/15/3/R51the biotinylated miRNA in each pull-down. SE, significantly enriched in
pull-down (5% FDR).
Additional file 8: Figure S7. Effect of site location on enrichment in
the biotin pull-down. (A) The odds ratios from Fisher’s exact tests for
an enrichment of transcripts with the indicated site type amongst the
putative target set including all transcripts. (B,C) Bar plots show the
coefficient estimates from a logistic regression of enrichment status on
site density (C) or site count (B). Only canonical transcripts were included.
Error bars indicate 95% confidence intervals.
Additional file 9: Figure S8. Hierarchical clustering of microarray data.
Clustering was performed using the plotSampleRelations function in the
lumi package. Total vertical distance between samples indicates similarity.
Arrays A and B were Illumina HT-12 version 4 arrays, and array C was
version 3. The miR-10b pull-down sample that clustered on a different
branch to the other miR-10a and miR-10b samples (miR-10b_arrayA_1:
red circle) was excluded.
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